Skip to content

Alteration of Myocardial Deformations in Diabetes: Relationship to Micro-angiopathy

Early Detection of Diabetic Cardiomyopathy by Analysis of Myocardial Deformations by Two-dimensional Speckle Tracking Strain Echocardiography and Relationship to Micro-angiopathy

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01220349
Acronym
ECHO-DIAB
Enrollment
61
Registered
2010-10-13
Start date
2011-01-01
Completion date
2012-10-01
Last updated
2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1

Brief summary

Despite careful monitoring of patients with diabetes, it is so far difficult to predict the occurrence of cardiac events in the evolution. As shown by various studies conducted in patients with diabetes, cardiac involvement can be detected by abnormalities of diastolic or systolic functions using non-invasive investigations such as echocardiography. For 4 years, the evaluation technique of myocardial deformations by two-dimensional speckle tracking strain by echocardiography is the subject of high hopes in the earlier detection of still asymptomatic cardiomyopathies. In the present study, the investigators hypothesized that this technique would improve the detection of myocardial contraction abnormalities in patients with insulin-dependent diabetes mellitus (IDDM), and would establish their association with micro-angiopathy, frequently encountered in these patients.

Detailed description

This is a single center case-control study based on routine care, designed to recruit patients with type 1 diabetes mellitus free from any other myocardiopathy. The inclusion will take place over a period of 24 months. No monitoring of patients (no follow-up) is provided under this protocol. The analysis will focus on the combination of the left ventricle myocardial deformations alteration revealed by the echocardiographic 2D strain analysis (\< 18% in absolute value), with the existence of micro-angiopathy in type 1 diabetes mellitus patients with preserved left ventricular ejection fraction ( ≥ 60%). Two hundred subjects with type 1 diabetes mellitus will be recruited: 100 subjects with impaired left ventricular myocardial deformation by 2D strain analysis (\< 18% in absolute value), constituting the 'cases' group and 100 subjects without alteration in myocardial deformation (global strain ≥ 18%).

Interventions

DEVICEEchocardiographic 2D strain analysis

Conventional transthoracic echocardiography with acquisitions for strain analysis by speckle tracking (2D strain)

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* aged between 18 and 45 years * with diagnosed Type 1 diabetes mellitus (with or without complications or peripheric vascular micro-angiopathy) * having a negative myocardial ischemic test (exercise echocardiography) in the previous month inclusion

Exclusion criteria

* Known or suspected coronary artery disease * atrial fibrillation * hypertension * moderate to severe valvular disease * sequelae of myocardial infarction * secondary or primary cardiomyopathy * myocardial conduction abnormalities * pregnancy or breastfeeding.

Design outcomes

Primary

MeasureTime frame
Measurement of the alteration of left ventricular myocardial strain (≤ 18% in absolute value) by echocardiography and the relationship to micro-angiopathy.Inclusion : Day 1

Secondary

MeasureTime frame
Analyses of this association (alteration of myocardial strain and micro-angiopathy) in relation with the duration of diabetes, and other co-factors such as dyslipidemia, unstable diabetes, and coexisting macro-angiopathy.Inclusion : Day 1

Countries

France

Contacts

PRINCIPAL_INVESTIGATORPatricia REANT, MD-PhD

University Hospital Bordeaux, France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 30, 2026